ALS Centre Netherlands

The ALS Centre Netherlands is the centre of expertise on ALS, PLS and PMA in the Netherlands. The centre is a cooperation of the University Medical Centre Utrecht and the Amsterdam Medical Centre. The centre schedules all diagnostic research and consultations for each patient on one day. More than 500 patients are diagnosed with ALS, PLS, PMA or one of its mimics each year. The ALS Centre Netherlands initiated Project Mine (www.projectmine.com), the largest research of the genetic basis of ALS worldwide. Additionally, research focuses on epidemiology, brain imaging and cognitive functioning of ALS patients.

ALS Centre Netherlands
Foundation year

1998

Director

Prof. dr. Leonard van den Berg

Principal investigator

Prof. dr. Leonard H. van den Berg, Prof. dr. Jan Veldink, Prof. dr. Jeroen Pasterkamp

Contact information
Address

Heidelberglaan 100
3584 XC, Utrecht
The Netherlands

Contact

Akke Albada (communications officer)

Phone

0031 88 755 7939

Email encals@umcutrecht.nl
Website Visit the website

Publications

  • Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; for the EMPOWER investigators. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurology 2013 Nov;12(11):1059-67
  • Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, Ince PG, Lin C, Miller RG, Mitsumoto H, Nicholson G, Ravits J, Shaw PJ, Swash M, Talbot K, Traynor BJ, van den Berg LH, Veldink JH, Vucic S, Kiernan MC. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013;12(3):310-22.
  • Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, Christiansen MW, Fairfax BP, Schramm K, Powell JE, Zhernakova A, Zhernakova DV, Veldink JH, Van den Berg LH, Karjalainen J, Withoff S, Uitterlinden AG, Hofman A, Rivadeneira F, \’t Hoen PA, Reinmaa E, Fischer K, Nelis M, Milani L, Melzer D, Ferrucci L, Singleton AB, Hernandez DG, Nalls MA, Homuth G, Nauck M, Radke D, Völker U, Perola M, Salomaa V, Brody J, Suchy-Dicey A, Gharib SA, Enquobahrie DA, Lumley T, Montgomery GW, Makino S, Prokisch H, Herder C, Roden M, Grallert H, Meitinger T, Strauch K, Li Y, Jansen RC, Visscher PM, Knight JC, Psaty BM, Ripatti S, Teumer A, Frayling TM, Metspalu A, van Meurs JB, Franke L. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nature Genet 2013;45(10):1238-43.
  • Van Blitterswijk M, Wang ET, Friedman BA, Keagle PJ, Lowe P, Leclerc AL, van den Berg LH, Housman DE, Veldink JH, Landers JE. Characterization of FUS Mutations in Amyotrophic Lateral Sclerosis Using RNA-Seq. PLoS One 2013;8(4):e60788.
  • Blauw HM, Barnes CP, van Vught PW, van Rheenen W, Verheul M, Cuppen E, Veldink JH, van den Berg LH. SMN1 gene duplications are associated with sporadic ALS. Neurology. 2012 Mar 13;78(11):776-80. Epub 2012 Feb 8. PubMed PMID: 22323753; PubMed Central PMCID: PMC3304946.

Have a look at the researchgate pages with full-text publications

Restricted information

Serving population
Serving population

100.000 to 1.000.000

Patient resources
Population based register

Yes

Clinic based register

Yes

Geographically matched controls

Yes

Number of skin samples

57

Number of spinal cord samples

25

Number of brain samples

25

Number of IPS cell samples

in development

Banks

Type ALS Patients Controls Other
DNA Bank 2650 3200 0
Serum Bank 2160 3080 0
RNA Bank 500 2380 0
MRI 380 259 94 PSMA, 69 PLS, 59 mimics
Research activities
Clinical management research

Yes

Neuro epidemiology

Yes

Neuro physiology

Yes

Neuro imaging

Yes

Neuro psychology

Yes

Neuro pathology

Yes

Genomics

Yes

Transcriptomics

Yes

Metabolomics

Yes

Clinical Trials - Industry sponsored

Name Type Patients
Masitinib trial ABscience (AB10015) phase 2/3 10
CHDR1417 phase 1 trial 18
Levals (ODM-109) phase 2a Levosimendan 5
TW001 Treeway phase 1 trial oral formulation edaravone 10
Vitality-ALS Cytokinetics phase 3 Tirasemtiv trial 10
VEGF trial NEWRON Sweden (sNN0029) phase 1 5
Benefit Trial 2013 (CK-2017357) Cytokinetics Tirasemtiv trial 12
Ozanezumab 2014 (GSK1223249) phase 2 22
Envision 2012 (KNS-760704) phase 3 Extension Study of Dexpramipexole in ALS 28
EMPOWER 2011 (KNS-760704) Dexpramipexole in ALS, phase 3 28
Alstar 2009 Alstar 2009 13
ONO-2506 (Ono Pharmaceutical Co. Ltd) ONO 2007 26

Clinical Trials - Investigator initiated

Name Type Patients
LITRA 2008 (Lithium)   LITRA 2008 (Lithium)   130
Natriumvalproaat 2005 Natriumvalproaat 2005 188